|
注册号: Registration number: |
ChiCTR2600120542 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-16 17:44:01 |
|
注册时间: Date of Registration: |
2026-03-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于人工智能算法与App的综合节律调控在睡眠觉醒时相延迟障碍患者中的疗效研究 |
|
Public title: |
Study on the Efficacy of Comprehensive Circadian Rhythm Regulation Based on Artificial Intelligence Algorithms and an App in Patients with Delayed Sleep-Wake Phase Disorder |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于人工智能算法与App的综合节律调控在睡眠觉醒时相延迟障碍患者中的疗效研究 |
|
Scientific title: |
Study on the Efficacy of Comprehensive Circadian Rhythm Regulation Based on Artificial Intelligence Algorithms and an App in Patients with Delayed Sleep-Wake Phase Disorder |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
周娱菁 |
研究负责人: |
张继辉 |
|
Applicant: |
Yujing Zhou |
Study leader: |
Jihui Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 130 5812 1234 |
研究负责人电话:
Study leader's |
+86 198 0209 9630 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
506131940@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangjihui@gzhmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省深圳市龙岗区中心城爱龙路6号 |
研究负责人通讯地址: |
广东省广州市荔湾区明心路36号 |
|
Applicant address: |
No. 6 Ailong Road, Zhongxincheng, Longgang District, Shenzhen City, Guangdong Province |
Study leader's address: |
No. 36 Mingxin Road, Liwan District, Guangzhou City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
深圳市龙岗区妇幼保健院 |
||
|
Applicant's institution: |
Maternal and Child Health Hospital of Shenzhen Longgang District |
||
|
研究负责人所在单位: |
广州医科大学附属脑科医院 |
||
|
Affiliation of the Leader: |
The Affilated Brain Hospital of Guangzhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2026)第(012)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州医科大学附属脑科医院伦理委员会 |
||
|
Name of the ethic committee: |
IRB, The Affiliated Brain Hospital of Guangzhou Medica |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-10 00:00:00 | ||
|
伦理委员会联系人: |
杨婵娟 |
||
|
Contact Name of the ethic committee: |
Chanjuan Yang |
||
|
伦理委员会联系地址: |
广东省广州市荔湾区明心路36号 |
||
|
Contact Address of the ethic committee: |
N0.36 Mingxin Road, Liwan District, Guangzhou City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8126 8229 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广州医科大学附属脑科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affilated Brain Hospital of Guangzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市荔湾区明心路36号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 36 Mingxin Road, Liwan District, Guangzhou City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
广州医科大学附属脑科医院科研启动经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Research Stat-up Funds from The Affilated Brain Hospital of Guangzhou Medical University |
||||||||||||||||||||||
|
研究疾病: |
睡眠觉醒时相延迟障碍 |
||||||||||||||||||||||
|
Target disease: |
Delayed Sleep-Wake Phase Disorder |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
打破传统治疗中针对单一授时因子靶点的局限性,验证数字化综合节律调控以及AI驱动的个体化综合节律调控的疗效 |
||||||||||||||||||||||
|
Objectives of Study: |
To overcome the limitations of traditional therapies that target a single zeitgeber, and to validate the therapeutic efficacy of digital comprehensive circadian rhythm regulation as well as AI-driven personalized circadian rhythm regulation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.合并符合DSM-5诊断标准的其他精神共病,包括双相情感障碍、精神分裂症、注意缺陷与多动障碍等; 2.过去三个月内有服用镇静催眠剂或外源性褪黑素等可能影响昼夜节律的药物; 3.有合并的脑器质性疾病、脑外伤史或其他重大躯体疾病; 4.近3个月有自伤或自杀行为; 5.患有青光眼、视网膜疾病、黄斑变性等眼部疾病,或正在服用已知的光敏性药物; 6.当前正参与其他干预性临床研究的被试; 7.本人或其法定监护人拒绝签署知情同意书。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Merge other mental comorbidities that meet the DSM-5 diagnostic criteria, including bipolar disorder, schizophrenia, attention deficit and hyperactivity disorder, etc.; 2. Have taken sedative-hypnotic drugs or exogenous melatonin or other drugs that may affect the circadian rhythm within the past three months; 3. Have concurrent organic brain diseases, history of brain trauma or other major physical diseases; 4. Have engaged in self-harm or suicidal behavior in the past three months; 5. Have eye diseases such as glaucoma, retinal diseases, macular degeneration, or are taking known photosensitive drugs; 6. Participants currently participating in other interventional clinical studies; 7. The individual or their legal guardian refuses to sign the informed consent form. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-06 00:00:00至 To 2027-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-03-16 00:00:00 至 To 2026-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用区组随机化法,通过“节律管家”小程序以固定随机种子预先生成1:1:1的随机分配序列组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using block randomization, a 1:1:1 random allocation sequence was pre-generated by the "Circadian Butler" mini-program with a fixed random seed. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究为双盲随机对照临床试验,受试者和评估者均不知道治疗分配组别。若发生紧急情况或不良事件,需要知道受试者治疗分配情况,可由研究人员按照规定程序告知组别和治疗信息。 |
|
Blinding: |
This study is a double-blind, randomized controlled clinical trial in which neither the participants nor the assessors are aware of the treatment allocation. In the event of an emergency or adverse event requiring disclosure of a participant's treatment assignment, the group and treatment information may be disclosed by the researcher in accordance with the specified procedures. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |